Sanjivani Paranteral Ltd
Incorporated in 1994, Sanjivani Parenteral Ltd is a research-based and export-oriented pharmaceutical company[1]
- Market Cap ₹ 212 Cr.
- Current Price ₹ 172
- High / Low ₹ 333 / 161
- Stock P/E 28.4
- Book Value ₹ 36.5
- Dividend Yield 0.29 %
- ROCE 28.5 %
- ROE 24.6 %
- Face Value ₹ 10.0
Pros
Cons
- Promoter holding is low: 31.2%
- Debtor days have increased from 59.2 to 86.8 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|
| 54.41 | 70.10 | 68.92 | |
| 46.18 | 59.76 | 58.87 | |
| Operating Profit | 8.23 | 10.34 | 10.05 |
| OPM % | 15.13% | 14.75% | 14.58% |
| 0.52 | 1.22 | 0.94 | |
| Interest | 0.25 | 0.59 | 0.66 |
| Depreciation | 0.93 | 0.62 | 0.67 |
| Profit before tax | 7.57 | 10.35 | 9.66 |
| Tax % | 18.63% | 21.84% | |
| 6.17 | 8.09 | 7.46 | |
| EPS in Rs | 5.28 | 6.81 | 6.21 |
| Dividend Payout % | -0.00% | -0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 10% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 8% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 76% |
| 3 Years: | 68% |
| 1 Year: | -48% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 25% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|
| Equity Capital | 11.68 | 11.88 | 12.28 |
| Reserves | 16.22 | 26.11 | 32.55 |
| 0.97 | 8.14 | 9.30 | |
| 14.53 | 32.07 | 18.90 | |
| Total Liabilities | 43.40 | 78.20 | 73.03 |
| 9.94 | 20.64 | 21.36 | |
| CWIP | -0.00 | 19.11 | 24.09 |
| Investments | -0.00 | -0.00 | -0.00 |
| 33.46 | 38.45 | 27.58 | |
| Total Assets | 43.40 | 78.20 | 73.03 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| -10.70 | 12.40 | |
| -12.21 | -21.91 | |
| 23.16 | 10.46 | |
| Net Cash Flow | 0.24 | 0.94 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Debtor Days | 31.53 | 86.85 |
| Inventory Days | 124.70 | 94.77 |
| Days Payable | 73.56 | 137.51 |
| Cash Conversion Cycle | 82.67 | 44.11 |
| Working Capital Days | 35.55 | -0.10 |
| ROCE % | 28.46% |
Documents
Announcements
-
Board Meeting Intimation for Intimation Of Notice Of Board Meeting To Be Held On Friday, 13Th February, 2026 Pursuant To Regulation 29(1)(A) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
10h - Board meeting on 13 Feb 2026 to approve unaudited Q3 results ended 31 Dec 2025.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
8 Jan - Certificate under regulation 74(5) for the Quarter ended 31st December, 2025
- Closure of Trading Window 27 Dec 2025
-
Announcement under Regulation 30 (LODR)-Change in Management
5 Dec 2025 - Appointment of Mr Basant Shrivastava as independent director from 11 Sept 2025 for five years, approved via postal ballot.
- Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot 5 Dec 2025
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Nov 2025Transcript PPT
-
Aug 2025Transcript PPT
-
May 2025Transcript PPT
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Aug 2024TranscriptAI SummaryPPT
-
Jul 2024TranscriptAI SummaryPPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT REC
-
Nov 2023TranscriptAI SummaryPPT
-
Nov 2023Transcript PPT
-
Oct 2023TranscriptAI SummaryPPT
-
May 2023TranscriptAI SummaryPPT
-
Mar 2023TranscriptAI SummaryPPT
-
Feb 2023TranscriptAI SummaryPPT
Business Overview:[1][2]
SPL is a WHO-GMP, DIGEMID, and DDA-certified pharmaceutical company specializing in high-quality parenteral and oral solid formulations. It serves key therapeutic areas including CNS, CVS, antibiotics, urology, anesthetics, gastroenterology, anti-diabetics, anti-fungals, anti-depressants, anti-allergics, muscle relaxants, and vitamin supplements.